ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "9826692a-01d3-4027-af3f-7fe32ca69944"}, "_deposit": {"id": "16371", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "16371"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00016371", "sets": ["456", "1103"]}, "item_7_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "The Therapeutic Approach to Diabetic Nephropathy"}]}, "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1998-10", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "10", "bibliographicPageEnd": "606", "bibliographicPageStart": "602", "bibliographicVolumeNumber": "112", "bibliographic_titles": [{"bibliographic_title": "新潟医学会雑誌"}, {"bibliographic_title": "新潟医学会雑誌", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The number of diabetic patients suffering from end stage renal disease is increasing year by year. It is important to prevent and postpone the initiation and progression of diabetic nephropathy (DN). The purpose of this review is to discuss preventive treatment in the field of DN. The target of glycemic control is reported such as below 7.2 % and 6.5 % in serum HbA1c level in IDDM and NIDDM patients, respectively. Since it is difficult to achieve these targets, aldose reductase inhibitor, protein kinase C-β inhibitor and other drugs such as aminoguanidine may be a treatment which can compensate incomplete glycemic control. Concerning to glomerular hyperfiltration, ACE inhibitor (ACEI) is more beneficial among antihypertensive agents. Since recommended target level of blood pressure (BP) is below 130/85 mmHg (JNC VI), it is difficult to control BP using only ACEI, and then combination with other antihypertensive drugs will be necessary in many cases. The preventive effects of dietary protein restriction in the progeression of DN will be proven by prospective controlled multicenter-study. Administration of prostaglandin (PG) E1, PGI2, and pancreatic elastase (PE) induce the reduction of urinary albumin excretion rate (UAER) in some patients with DN. Long term effect of these agents remains to be investigated. Glycosaminoglycans (GAGs) including heparin is reported to reduce UAER in human and animal models of DN. GAGs with low anticoagulation action is necessary for clinical use. Concerning the clinical stage of DN, therapeutic approach to DN is summarized.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "104352", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Karasawa, Ryou"}]}]}, "item_7_publisher_7": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "新潟医学会"}]}, "item_7_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "柄澤, 良"}], "nameIdentifiers": [{"nameIdentifier": "104346", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鈴木, 芳樹"}], "nameIdentifiers": [{"nameIdentifier": "104347", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "笠井, 昭男"}], "nameIdentifiers": [{"nameIdentifier": "104348", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "阪田, 郁"}], "nameIdentifiers": [{"nameIdentifier": "104349", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "成田, 一衛"}], "nameIdentifiers": [{"nameIdentifier": "104350", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "荒川, 正昭"}], "nameIdentifiers": [{"nameIdentifier": "104351", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "112(10)_602-606.pdf", "filesize": [{"value": "906.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 906300.0, "url": {"label": "112(10)_602-606.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/16371/files/112(10)_602-606.pdf"}, "version_id": "12906ac5-9a1a-4d95-805a-e7480666bfce"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "diabetic nephropathy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "therapeutic approach", "subitem_subject_scheme": "Other"}, {"subitem_subject": "糖尿病性腎症", "subitem_subject_scheme": "Other"}, {"subitem_subject": "治療", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)"}, {"subitem_title": "2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["456", "1103"], "permalink_uri": "http://hdl.handle.net/10191/46253", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-02-08"}, "publish_date": "2017-02-08", "publish_status": "0", "recid": "16371", "relation": {}, "relation_version_is_last": true, "title": ["2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)"], "weko_shared_id": null}
  1. 0 資料タイプ別
  2. 03 紀要論文
  1. 250 大学院医歯学総合研究科(医)
  2. 20 紀要
  3. 02 新潟医学会雑誌
  4. 第112巻第10号

2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)

http://hdl.handle.net/10191/46253
http://hdl.handle.net/10191/46253
3d61c1f3-b4e3-465f-9be3-232ba7b6f5fb
名前 / ファイル ライセンス アクション
112(10)_602-606.pdf 112(10)_602-606.pdf (906.3 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2017-02-08
タイトル
タイトル 2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)
タイトル
言語 en
タイトル 2)糖尿病性腎症の治療(シンポジウム 糖尿病合併症の治療, 第535回新潟医学会)
言語
言語 jpn
キーワード
主題Scheme Other
主題 diabetic nephropathy
キーワード
主題Scheme Other
主題 therapeutic approach
キーワード
主題Scheme Other
主題 糖尿病性腎症
キーワード
主題Scheme Other
主題 治療
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
その他のタイトル
その他のタイトル The Therapeutic Approach to Diabetic Nephropathy
著者 柄澤, 良

× 柄澤, 良

WEKO 104346

柄澤, 良

Search repository
鈴木, 芳樹

× 鈴木, 芳樹

WEKO 104347

鈴木, 芳樹

Search repository
笠井, 昭男

× 笠井, 昭男

WEKO 104348

笠井, 昭男

Search repository
阪田, 郁

× 阪田, 郁

WEKO 104349

阪田, 郁

Search repository
成田, 一衛

× 成田, 一衛

WEKO 104350

成田, 一衛

Search repository
荒川, 正昭

× 荒川, 正昭

WEKO 104351

荒川, 正昭

Search repository
著者別名
識別子 104352
識別子Scheme WEKO
姓名 Karasawa, Ryou
抄録
内容記述タイプ Abstract
内容記述 The number of diabetic patients suffering from end stage renal disease is increasing year by year. It is important to prevent and postpone the initiation and progression of diabetic nephropathy (DN). The purpose of this review is to discuss preventive treatment in the field of DN. The target of glycemic control is reported such as below 7.2 % and 6.5 % in serum HbA1c level in IDDM and NIDDM patients, respectively. Since it is difficult to achieve these targets, aldose reductase inhibitor, protein kinase C-β inhibitor and other drugs such as aminoguanidine may be a treatment which can compensate incomplete glycemic control. Concerning to glomerular hyperfiltration, ACE inhibitor (ACEI) is more beneficial among antihypertensive agents. Since recommended target level of blood pressure (BP) is below 130/85 mmHg (JNC VI), it is difficult to control BP using only ACEI, and then combination with other antihypertensive drugs will be necessary in many cases. The preventive effects of dietary protein restriction in the progeression of DN will be proven by prospective controlled multicenter-study. Administration of prostaglandin (PG) E1, PGI2, and pancreatic elastase (PE) induce the reduction of urinary albumin excretion rate (UAER) in some patients with DN. Long term effect of these agents remains to be investigated. Glycosaminoglycans (GAGs) including heparin is reported to reduce UAER in human and animal models of DN. GAGs with low anticoagulation action is necessary for clinical use. Concerning the clinical stage of DN, therapeutic approach to DN is summarized.
書誌情報 新潟医学会雑誌
en : 新潟医学会雑誌

巻 112, 号 10, p. 602-606, 発行日 1998-10
出版者
出版者 新潟医学会
ISSN
収録物識別子タイプ ISSN
収録物識別子 00290440
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AN00182415
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 15:41:57.334956
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3